 Alexis Leal
Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 2 | 2015 | 27 | 0.960 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2018 | 1442 | 0.940 |
Why?
| | Antiemetics | 4 | 2018 | 39 | 0.820 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2023 | 62 | 0.810 |
Why?
| | Immunoconjugates | 2 | 2023 | 90 | 0.780 |
Why?
| | Phlebitis | 2 | 2014 | 11 | 0.580 |
Why?
| | Morpholines | 2 | 2014 | 108 | 0.540 |
Why?
| | Reproductive History | 1 | 2015 | 13 | 0.520 |
Why?
| | Hematologic Neoplasms | 1 | 2017 | 138 | 0.520 |
Why?
| | Antineoplastic Agents | 5 | 2023 | 2009 | 0.510 |
Why?
| | Hormone Replacement Therapy | 1 | 2015 | 81 | 0.490 |
Why?
| | Colorectal Neoplasms | 4 | 2024 | 639 | 0.470 |
Why?
| | Breast Neoplasms | 2 | 2017 | 2059 | 0.450 |
Why?
| | Postmenopause | 1 | 2015 | 310 | 0.450 |
Why?
| | Cancer Survivors | 1 | 2017 | 234 | 0.430 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2014 | 121 | 0.430 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 517 | 0.420 |
Why?
| | Glutathione | 1 | 2014 | 334 | 0.410 |
Why?
| | Nausea | 4 | 2018 | 113 | 0.390 |
Why?
| | Vomiting | 4 | 2018 | 132 | 0.390 |
Why?
| | Decision Making | 1 | 2017 | 861 | 0.360 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2848 | 0.330 |
Why?
| | Physicians | 1 | 2017 | 836 | 0.320 |
Why?
| | Neoplasms | 4 | 2023 | 2340 | 0.320 |
Why?
| | Aged, 80 and over | 8 | 2021 | 6936 | 0.310 |
Why?
| | Cyclophosphamide | 3 | 2017 | 229 | 0.280 |
Why?
| | Doxorubicin | 3 | 2017 | 310 | 0.260 |
Why?
| | Aged | 12 | 2023 | 20859 | 0.250 |
Why?
| | Paclitaxel | 2 | 2017 | 200 | 0.240 |
Why?
| | Middle Aged | 13 | 2023 | 29112 | 0.220 |
Why?
| | Oncogene Proteins, Viral | 1 | 2023 | 20 | 0.220 |
Why?
| | Survival Rate | 4 | 2021 | 1799 | 0.200 |
Why?
| | Fluorouracil | 1 | 2022 | 161 | 0.200 |
Why?
| | Antigens, Neoplasm | 2 | 2024 | 229 | 0.190 |
Why?
| | Prognosis | 3 | 2020 | 3616 | 0.180 |
Why?
| | DNA Mismatch Repair | 1 | 2020 | 38 | 0.170 |
Why?
| | Papillomavirus Infections | 1 | 2023 | 268 | 0.170 |
Why?
| | Patient Compliance | 2 | 2021 | 571 | 0.160 |
Why?
| | Vaccines | 1 | 2024 | 380 | 0.160 |
Why?
| | Female | 13 | 2021 | 64889 | 0.160 |
Why?
| | Humans | 19 | 2024 | 125131 | 0.150 |
Why?
| | Drug Design | 1 | 2018 | 162 | 0.150 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4824 | 0.150 |
Why?
| | Insurance Claim Review | 1 | 2017 | 70 | 0.140 |
Why?
| | Office Visits | 1 | 2017 | 95 | 0.140 |
Why?
| | Mastectomy | 1 | 2017 | 130 | 0.140 |
Why?
| | Codon | 1 | 2017 | 90 | 0.140 |
Why?
| | Eligibility Determination | 1 | 2017 | 68 | 0.140 |
Why?
| | Adult | 9 | 2023 | 33167 | 0.140 |
Why?
| | Lymph Node Excision | 1 | 2017 | 159 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 369 | 0.130 |
Why?
| | Infusions, Intravenous | 2 | 2014 | 391 | 0.130 |
Why?
| | Immunotherapy | 1 | 2020 | 499 | 0.130 |
Why?
| | Drug Prescriptions | 1 | 2018 | 274 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 677 | 0.130 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2017 | 205 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 759 | 0.120 |
Why?
| | Iowa | 1 | 2013 | 26 | 0.110 |
Why?
| | Complementary Therapies | 1 | 2014 | 73 | 0.110 |
Why?
| | Placebos | 1 | 2014 | 208 | 0.110 |
Why?
| | Carboplatin | 1 | 2014 | 144 | 0.110 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2014 | 78 | 0.110 |
Why?
| | Medical Order Entry Systems | 1 | 2013 | 44 | 0.110 |
Why?
| | Anthropometry | 1 | 2013 | 205 | 0.110 |
Why?
| | Prospective Studies | 2 | 2015 | 6818 | 0.110 |
Why?
| | Hip Prosthesis | 1 | 2013 | 35 | 0.110 |
Why?
| | Hip Dislocation | 1 | 2013 | 59 | 0.100 |
Why?
| | Conscious Sedation | 1 | 2013 | 86 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1300 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2013 | 119 | 0.100 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1251 | 0.100 |
Why?
| | Retrospective Studies | 7 | 2021 | 13708 | 0.100 |
Why?
| | Women's Health | 1 | 2013 | 282 | 0.090 |
Why?
| | Life Style | 1 | 2013 | 442 | 0.090 |
Why?
| | Risk Factors | 2 | 2015 | 9549 | 0.090 |
Why?
| | Survivors | 1 | 2014 | 460 | 0.090 |
Why?
| | Double-Blind Method | 1 | 2014 | 1725 | 0.080 |
Why?
| | Male | 9 | 2021 | 60792 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2013 | 563 | 0.080 |
Why?
| | Young Adult | 4 | 2018 | 11384 | 0.080 |
Why?
| | Motor Activity | 1 | 2013 | 689 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2015 | 3326 | 0.080 |
Why?
| | Health Status | 1 | 2013 | 794 | 0.070 |
Why?
| | Cohort Studies | 1 | 2017 | 5348 | 0.070 |
Why?
| | Mutation | 1 | 2017 | 3520 | 0.070 |
Why?
| | Age Factors | 3 | 2021 | 3152 | 0.070 |
Why?
| | Body Mass Index | 1 | 2013 | 2174 | 0.060 |
Why?
| | Smoking | 1 | 2013 | 1635 | 0.060 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2023 | 10 | 0.050 |
Why?
| | Receptors, Enterotoxin | 1 | 2023 | 4 | 0.050 |
Why?
| | HLA-A Antigens | 1 | 2023 | 50 | 0.050 |
Why?
| | Human papillomavirus 16 | 1 | 2023 | 25 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 41 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 238 | 0.050 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 64 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2023 | 186 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 5061 | 0.050 |
Why?
| | Camptothecin | 1 | 2022 | 100 | 0.050 |
Why?
| | Adolescent | 2 | 2018 | 19411 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2013 | 2325 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2023 | 364 | 0.050 |
Why?
| | Antibodies | 1 | 2023 | 396 | 0.050 |
Why?
| | Obesity | 1 | 2013 | 2805 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 517 | 0.040 |
Why?
| | Sex Factors | 2 | 2017 | 1901 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2020 | 32 | 0.040 |
Why?
| | Ipilimumab | 1 | 2020 | 30 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 338 | 0.040 |
Why?
| | Peptides | 1 | 2024 | 884 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 912 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2023 | 2026 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 149 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 200 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2018 | 68 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1080 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 292 | 0.040 |
Why?
| | Animals | 1 | 2018 | 34345 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2017 | 263 | 0.030 |
Why?
| | Patient Selection | 1 | 2020 | 725 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 666 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2022 | 2913 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1006 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 573 | 0.030 |
Why?
| | Anthracyclines | 1 | 2014 | 42 | 0.030 |
Why?
| | United States | 2 | 2021 | 13613 | 0.030 |
Why?
| | Apoptosis | 1 | 2022 | 2553 | 0.030 |
Why?
| | United Kingdom | 1 | 2013 | 260 | 0.030 |
Why?
| | Logistic Models | 1 | 2013 | 2040 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 9790 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2013 | 875 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 1970 | 0.010 |
Why?
|
|
Leal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|